Akademik Veri Yönetim Sistemi
Current Dermatology Reports, 2024 (ESCI)
Purpose of Review: SDRIFE (Symmetrical drug-related intertriginous and flexural exanthema) is type IV hypersensitivity drug-related skin eruption. Numerous drugs have previously been associated with SDRIFE; however few cases associated with the coronavirus disease 2019 (COVID-19) vaccine have been reported. Here, we present a case in which SDRIFE was generated following administration of the CoronaVacTM (SinoVac Biotech Corporation) vaccine. A literature review was also conducted to summarize the various cases of SDRIFE induced by the coronavirus disease 2019 (COVID-19) vaccine. Recent Findings: SDRIFE is a rare complication of COVID-19 vaccines. Here, we reviewed all 14 cases reported in the literature, along with our own case. Three cases, including ours, have been reported with the CoronaVacTM vaccine, a purified, inactivated antigen vaccine produced by the SinoVac Biotech Corporation. Summary: SDRIFE-like eruptions are thought to constitute a delayed type IV immune response to COVID-19 vaccines. However, further studies are required to determine the possible underlying mechanisms involved. The use of COVID-19 vaccines is affecting an increasing number of people worldwide. Therefore, clinicians should be informed of any adverse reactions that may occur. Knowing these reactions can help us illuminate the possible mechanisms of the COVID-19 and other COVID-19 vaccines.